ZELRISTY
Live / Applied — Extension of time to oppose received (as of 09 Sept 2026)
What this means for you
Not registered yet, but its 27 Mar 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99729374
- Mark type
- Stylized text
- Filed
- 27 Mar 2026
- Published for opposition
- 11 Aug 2026
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene therapy, genome editing, genome modification, cell therapy, cellular modification, and tissue modification for use in human therapeutics for the treatment of Sickle Cell Disease
Owner
- Beam Therapeutics Inc., Cambridge, MA, US
- Beam Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 09 Sept 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 11 Aug 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Aug 2026 — PUBLISHED FOR OPPOSITION
- 05 Aug 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Jul 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Jun 2026 — ASSIGNED TO EXAMINER
- 27 Mar 2026 — APPLICATION FILING RECEIPT MAILED
- 27 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Mar 2026 — NEW APPLICATION ENTERED